News
KPTI
1.065
+5.45%
0.055
Karyopharm Therapeutics (KPTI) Receives a Buy from RBC Capital
TipRanks · 2d ago
Weekly Report: what happened at KPTI last week (0603-0607)?
Weekly Report · 2d ago
Hold Rating on Karyopharm Amid Competitive Landscape and Pending Data Outcomes
TipRanks · 06/04 08:06
Karyopharm Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 06/03 10:36
Paramount Global Shares Rise 6.6% on Revised Skydance Offer
Dow Jones · 06/03 10:27
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Benzinga · 06/03 10:26
Buy Rating for Karyopharm on Strong Xpovio Clinical Data and Favorable Safety Profile
TipRanks · 06/03 10:16
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks · 06/03 09:39
Weekly Report: what happened at KPTI last week (0527-0531)?
Weekly Report · 06/03 09:06
Karyopharm Shareholders Back Expansion and Elect Directors
TipRanks · 05/31 12:58
Karyopharm Therapeutics Inc: Registration statement under Securities Act of 1933
Press release · 05/30 22:23
Karyopharm Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 05/30 22:23
Karyopharm Therapeutics Files For Shelf Registration Of Up To 45.8M Shares Of Common Stock By Selling Stockholders
Benzinga · 05/30 20:48
KARYOPHARM THERAPEUTICS INC FILES FOR SHELF OF UP TO 45.8 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 05/30 20:46
Weekly Report: what happened at KPTI last week (0520-0524)?
Weekly Report · 05/27 09:06
Weekly Report: what happened at KPTI last week (0513-0517)?
Weekly Report · 05/20 09:06
Weekly Report: what happened at KPTI last week (0506-0510)?
Weekly Report · 05/13 09:06
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
TipRanks · 05/10 05:41
Maintaining Hold on Karyopharm: A Balancing Act Between Financial Restructuring and Clinical Milestones
TipRanks · 05/10 05:32
Karyopharm Therapeutics Inc. Quarterly Report for the Quarter Ended March 31, 2024
Press release · 05/09 15:48
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.